Monte Rosa Therapeutics, Inc. (GLUE)

16.35 +0.04 (+0.25%) USD  |  NASDAQ  |  Dec 15, 14:42
More

Monte Rosa Therapeutics Research and Development Expense (Quarterly): 34.58M for Sept. 30, 2025

Research and Development Expense (Quarterly) Chart

View Research and Development Expense (Quarterly) for GLUE.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
Novartis AG 2.857B
AVITA Medical, Inc. 3.748M
ENvue Medical, Inc. 0.221M
Mirum Pharmaceuticals, Inc. 42.90M
Day One Biopharmaceuticals, Inc. 31.42M